# The SIBERIA Trial (Acculink™ Versus CGuard™)

> **NCT03488199** · NA · COMPLETED · sponsor: **Meshalkin Research Institute of Pathology of Circulation** · enrollment: 100 (actual)

## Conditions studied

- Patients With Aterosclerotic Carotid Stenosis
- Symptomatic Patients (Stenosis > 50%)
- Asymptomatic Patients (Stenosis ≥80%)

## Interventions

- **DEVICE:** Stent Acculink ™
- **DEVICE:** CGuardTM™

## Key facts

- **NCT ID:** NCT03488199
- **Lead sponsor:** Meshalkin Research Institute of Pathology of Circulation
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-11
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-03-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03488199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03488199, "The SIBERIA Trial (Acculink™ Versus CGuard™)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03488199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*